Drug Trial Radar · NCT03874897
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Mar 26, 2019
Primary completion
Mar 20, 2021
Study completion Jan 26, 2024
Sponsor
- Lead sponsor
- Peking UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CARsgen Therapeutics Co., Ltd.
- First posted
- Mar 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
Conditions
- Advanced Solid Tumor
Interventions
CAR-CLDN18.2 T-CellsDrug
Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2
PD-1 Monoclonal AntibodyDrug
Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
ChemotherapyDrug
First-line systemic therapy according to physician's choice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: 28 days of single infusion
- Maximum tolerated dose (MTD)Time frame: 28 days of single infusion
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Department of GI Oncology, Peking University Cancer Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
The First Affiliated Hospital , Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.